Advancements and Updates in Therapies for CLL - Episode 1

NCCN Recommendations: Frontline CLL Treatment Options

May 29, 2020

Now Viewing

EP. 1: NCCN Recommendations: Frontline CLL Treatment Options

EP. 2: Front-Line Therapy Decision Criteria

EP. 3: Limited-Duration Therapy Based on MRD Testing

EP. 4: Newly Diagnosed CLL: BTK Inhibitor Monotherapy

EP. 5: Developing Clinical Trials for Newly Diagnosed Disease

EP. 6: First-Line Therapy for Treatment-Naïve Patients

EP. 7: BTK Inhibitor Toxicity Management

EP. 8: Oral Oncolytics Versus Intravenous: Safety and Efficacy

EP. 9: Oral Therapy Adverse Events

EP. 10: Intravenous Versus Oral Delivery: Medical Benefits

EP. 11: Pharmacy-Led Oral Chemotherapy Management Programs

EP. 12: Optimizing Success for Community Physicians

EP. 13: Experts Outline Best Practices in the Treatment of Chronic Lymphocytic Leukemia

EP. 14: Experts Discuss Treatment Considerations for Chronic Lymphocytic Leukemia

In this Directions in Oncology Pharmacy Insights video series, Alison Duffy, PharmD, BCOP, University of Maryland School of Pharmacy, and Cody Steeves, PharmD, BCOP, Biologics by McKesson, discuss advancements and updates in therapies for chronic lymphocytic leukemia (CLL). This first segment focuses on NCCN recommendations for frontline treatment options.